ShockWave Medical - SWAV Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ShockWave Medical in the last twelve months. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SWAV shares.
View SWAV analyst ratings or view top-rated stocks.

8 brokerages have issued 1 year price targets for ShockWave Medical's stock. Their SWAV share price forecasts range from $165.00 to $338.00. On average, they anticipate the company's stock price to reach $244.86 in the next year. This suggests that the stock has a possible downside of 12.1%.
View analysts price targets for SWAV or view top-rated stocks among Wall Street analysts.

ShockWave Medical's stock was trading at $178.33 on January 1st, 2022. Since then, SWAV shares have increased by 56.3% and is now trading at $278.65.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our SWAV earnings forecast.

ShockWave Medical, Inc. (NASDAQ:SWAV) announced its earnings results on Monday, August, 8th. The company reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.25. The company had revenue of $120.70 million for the quarter, compared to analyst estimates of $107.51 million. ShockWave Medical had a trailing twelve-month return on equity of 21.25% and a net margin of 15.11%. The company's revenue for the quarter was up 115.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.01) earnings per share.

ShockWave Medical issued an update on its FY 2022 earnings guidance on Tuesday, September, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $465.00 million-$475.00 million, compared to the consensus revenue estimate of $448.64 million.

8 employees have rated ShockWave Medical Chief Executive Officer Doug Godshall on Glassdoor.com. Doug Godshall has an approval rating of 89% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other ShockWave Medical investors own include NVIDIA (NVDA), Walt Disney (DIS), Block (SQ), Trade Desk (TTD), Salesforce (CRM), Roku (ROKU), PayPal (PYPL), DexCom (DXCM), Alibaba Group (BABA) and Okta (OKTA).

(SWAV) raised $75 million in an initial public offering (IPO) on Thursday, March 7th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

ShockWave Medical trades on the NASDAQ under the ticker symbol "SWAV."

Shares of SWAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SWAV stock can currently be purchased for approximately $278.65.

ShockWave Medical (NASDAQ:SWAV) has a market capitalization of $9.97 billion and generates $237.15 million in revenue each year. The company earns $-9,140,000.00 in net income (profit) each year or $1.46 on an earnings per share basis.

The company employs 657 workers across the globe.

ShockWave Medical's mailing address is 5403 Betsy Ross Drive, Santa Clara CA, 95054. The official website for the company is www.shockwavemedical.com. The company can be reached via phone at (510) 279-4262 or via email at investors@shockwavemedical.com.